The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

123 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate which is the most appropriate parameter correlates with clinical effectiveness of vancomycin: trough drug level or AUC/MIC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vancomycin Dose Adjustments Comparing Trough Levels to The AUC/MIC Method Using a Bayesian Approach in a Hospitalized Adult Population

NCT04756895

Vancomycin Adult Area Under Curve

COMPLETED NA

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

NCT00862862

Staphylococcus Aureus

TERMINATED

Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?

NCT05395520

MRSA

UNKNOWN

Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy

NCT01352936

Staphylococcus Aureus Bacteremia

UNKNOWN

Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin

NCT02443064

Blood Stream Infections Endocarditis MRSA

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Several studies have shown AUC/MIC to be the better pharmacokinetic-pharmacodynamic parameter for clinical effectiveness of vancomycin. However, the 2009 consensus guideline for vancomycin therapeutic monitoring continued to recommend trough serum concentration monitoring in the clinical setting. In 2011, Patel et al showed that highly difference between AUC(72-96h) and Cmin(96h). Different dosing and creatinine clearance may reach the same trough drug level with different AUC. The investigators wonder whether trough drug level can serve as a substitute marker for AUC and as a parameter for vancomycin therapeutic monitoring.

In this study, the investigators will calculate AUC/MIC of vancomycin with published formula, analyze its correlation with patient's clinical outcome and compare that with trough drug level.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methicillin-resistant Staphylococcus Aureus Septicemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inpatients of National Taiwan University Hospital
* Age above or equal to 20 years old
* Positive methicillin-resistant Staphylococcus aureus blood culture
* Receiving vancomycin therapy for definitive use
* Undergoing therapeutic drug monitoring (had serum vancomycin concentration level)

Exclusion Criteria

* Age below 20 years old
* Without details of vancomycin dose and frequency
* Vancomycin treatment shorter than 72 hours
* Without renal function data (serum creatinine level, creatinine clearance)
* Without infection-related clinical outcomes (lab data such as white blood cell count , seg, C reactive protein , body temperature records)
* Receiving renal replacement therapy
* Therapeutic drug monitoring before reaching steady state
* With abnormal and undefined serum concentration

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No